Discontinued — last reported Q4 '24
Basaglar® — Revenue
Eli Lilly Basaglar® — Revenue increased by 9.5% to $176.90M in Q4 2024 compared to the prior quarter. Year-over-year, this metric declined by 4.5%, from $185.20M to $176.90M. Over 3 years (FY 2021 to FY 2024), Basaglar® — Revenue shows a downward trend with a -8.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market adoption and effective commercial execution, while a decrease may signal increased competition from biosimilars or shifts in patient treatment preferences.
Detailed definition
This metric represents the total net sales generated from the Basaglar product line, a long-acting insulin analog used f...
Peer comparison
Comparable to revenue reporting for specific branded pharmaceutical products or therapeutic franchises at peer companies like Novo Nordisk or Sanofi.
lly_segment_basaglar_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $210.70M | $192.80M | $242.40M | $191.50M | $174.20M | $193.00M | $201.70M | $209.30M | $154.20M | $179.60M | $185.20M | $157.60M | $180.80M | $161.60M | $176.90M |
| QoQ Change | — | -8.5% | +25.7% | -21.0% | -9.0% | +10.8% | +4.5% | +3.8% | -26.3% | +16.5% | +3.1% | -14.9% | +14.7% | -10.6% | +9.5% |
| YoY Change | — | — | — | — | -17.3% | +0.1% | -16.8% | +9.3% | -11.5% | -6.9% | -8.2% | -24.7% | +17.3% | -10.0% | -4.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's basaglar® — revenue?
- Eli Lilly (LLY) reported basaglar® — revenue of $176.90M in Q4 2024.
- How has Eli Lilly's basaglar® — revenue changed year-over-year?
- Eli Lilly's basaglar® — revenue decreased by 4.5% year-over-year, from $185.20M to $176.90M.
- What is the long-term trend for Eli Lilly's basaglar® — revenue?
- Over 3 years (2021 to 2024), Eli Lilly's basaglar® — revenue has grown at a -8.8% compound annual growth rate (CAGR), from $892.50M to $676.90M.
- What does basaglar® — revenue mean?
- The total revenue earned from sales of the Basaglar insulin product.